Pharmacogenomics in epithelial ovarian cancer first-line treatment outcome: validation of GWAS-associated NRG3 rs1649942 and BRE rs7572644 variants in an independent cohort

2018 ◽  
Vol 19 (1) ◽  
pp. 25-32
Author(s):  
Ricardo Pinto ◽  
Joana Assis ◽  
Augusto Nogueira ◽  
Carina Pereira ◽  
Sara Coelho ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Treatment Outcome ◽  
Epithelial Ovarian Cancer ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment ◽  
Independent Cohort

P168 Influence of first-line treatment for epithelial ovarian cancer on the immune system

2019 ◽  
Author(s):  
T Baert ◽  
C Landolfo ◽  
J Ceusters ◽  
G Thirion ◽  
A Van Hoylandt ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
Epithelial Ovarian Cancer ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Weekly topotecan as first-line treatment for recurrent or persistent epithelial ovarian cancer (EOC)

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 5111-5111
Author(s):  
T. Safra ◽  
J. Menczer ◽  
M. Inbar ◽  
E. En-Shem ◽  
M. Glezerman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study

2003 ◽  
Vol 91 (1) ◽  
pp. 32-38 ◽  
Author(s):  
D Belpomme ◽  
I Krakowski ◽  
M Beauduin ◽  
T Petit ◽  
J.L Canon ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document